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Available online 4 June 2012AbstractAerobic exercise is associated with changes in plasma fatty acid profile, whereas caffeine is known to exert action on lipolysis. However, the
majority of this previous work has studied fatty acids as a single entity and not on an individual fatty acid basis, despite their differing roles and
functions. The aim of this study was to assess the effect of 5 mg/kg body mass caffeine on maximal exercise and total plasma fatty acids profile.
In a crossover, double-blinded, randomized placebo-controlled trial involving 20 untrained men who were not customary caffeine consumers,
performance and ventilatory responses during an incremental maximal aerobic exercise protocol, along with plasma total fatty acid profile (by
gas chromatography), were assessed. Exercise time to exhaustion ( p < 0.01), maximum power output ( p < 0.05) and maximum oxygen
consumption increased ( p < 0.05) significantly after caffeine ingestion. After exercise with caffeine, saturated fatty acids as a proportion of total
fatty acids increased ( p < 0.05), while decreases in trans-oleic acid ( p < 0.05), arachidic acid ( p < 0.05) and delta 9.2 desaturation index
( p < 0.05) were found. The ingestion of caffeine before maximal incremental exercise produces an ergogenic effect, with the combination of
caffeine and improved exercise performance resulting in greater relative fat oxidation and post-exercise differences in individual plasma free
fatty acid proportions.
Copyright  2012, The Society of Chinese Scholars on Exercise Physiology and Fitness. Published by Elsevier (Singapore) Pte Ltd. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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There is a strong connection between the free fatty acid
profile and health status. Greater concentrations of saturated
fatty acids are associated with potential deleterious health
outcomes (e.g., hypertension or obesity), whereas unsaturated
fatty acids may play a cardiometabolic protective role.1
Aerobic exercise, with its reliance on fatty acids for energy
production,2 induces alterations in fatty acid profile towards* Corresponding author. Faculty of Sport Sciences, Avenida de la Universidad,
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access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-ndimproved health outcomes. Certain substances are also for-
warded as conferring beneficial modifications to the fatty acid
profile, with one such substance being caffeine, a trime-
thylxanthine commonly found in our diet and in some medi-
cations.3 Caffeine action and its influence on fat metabolism
have been well studied, with several studies showing that this
alkaloid can enhance fatty acid mobilization from adipose
tissue stores to mitochondria for oxidation during physical
activity.4e6 However, in most studies, fatty acids are studied as
a single entity as opposed to analyzing them according to type,
despite differing individual roles and functions. The limited
work that has analyzed changes in the profile of individual
plasma fatty acids following exercise7 and caffeine ingestion8cise Physiology and Fitness. Published by Elsevier (Singapore) Pte Ltd. This is an open
/4.0/).
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a more potent influence on lipolysis and changes in individual
plasma fatty acid concentrations than either stimulus alone.
Alterations to the total plasma fatty acids profile may have
potential health implications, with the unsaturated-to-saturated
fatty acids ratio associated with cardiovascular disease
risk.9 Caffeine alone can act as a pro-oxidant, increasing
catecholamine production,10 and catecholamine metabolic
inactivation can augment lipid peroxidation,11 converting
unsaturated fatty acids to saturated small-to-medium-chain
fatty acids. However, little is known about modifications in
individual fatty acid profiles under the combined conditions of
caffeine and exercise.
Therefore, the aim of this study was to assess the effect of
caffeine ingestion on the performance of an incremental
exercise test and the associated changes in the plasma free
fatty acid profile. The outcomes generate new knowledge
about the interaction of caffeine on fat metabolism during
maximal exercise performance and, in particular, its influence
on individual plasma fatty acids with differing roles and
functions.
Materials and methodsParticipantsParticipants were 20 men who reported no routine caffeine
consumption and did not exercise regularly. Participant char-
acteristics were: age 20.9  1.3 years, height 175.3  6.1 cm,
body mass (BM) 71.0  5.5 kg, and body fat 10.1  1.1%.
Values were calculated using anthropometric techniques.
Criteria of <1 hour of physical exercise per week for the past
6 months and no endurance training history were used to
establish the “untrained status” of the participants.
Participants did not receive any form of nutritional
supplementation before or during the study other than the
caffeine used for the trials. During the week of testing, diet
was controlled and fixed at 2000e2500 kcal/day, comprising
w60% carbohydrate, w25% fat and w15% protein. The last
meal (breakfast) before the trials was consumed 3 hours before
exercise, and it was standardized for all participants, con-
taining 1.5 g carbohydrate per kilogram BM, while main-
taining the same relative composition of macronutrients as
outlined above.
Participants were informed of the procedures of this study
and gave written consent.Experimental designThe experimental protocol was a crossover, double-blinded,
randomized design in which all participants performed incre-
mental maximal effort cycling under two conditions: placebo
and caffeine.12 Placebo capsules were empty. Caffeine
capsules were prepared using pure caffeine (Sigma. Germany)
relative to participant BM at a concentration of 5 mg/kg
BM.3,13 Participants ingested capsules (with water) at
60 minutes before the trials.The two cycling trials, placebo or caffeine, were performed
in the morning and separated by 3 days to provide sufficient
recovery. Exercise trials consisted of an incremental maximal
test on a cycle ergometer (Ergo-metrics 900, Ergo-line.
Germany). The starting intensity was 100 W, increasing by
50 W every 2 minutes until 300 W, when intensity was
increased by 25 W every 2 minutes until exhaustion.MeasurementsExpired gases, ventilation and heart rate were measured
during exercise using a Medical Graphics gas analyzer (MGC,
model no. 762014-102. USA) and a heart rate monitor (Polar S
720. Finland) with interface (Polar Advantage interface).
Blood samples were obtained from the antecubital vein in
the supine position before placebo or caffeine ingestion, and
immediately after exercise for assessment of plasma caffeine
concentration and plasma free fatty acids profile. Plasma was
obtained by centrifugation and was stored at 20 C until
analysis. Plasma samples were analyzed using gas chromato-
graphic techniques to determine total fatty acids profile:
saturated C12:0, C14:0, C16:0, C18:0, C20:0; mono-
unsaturated C16:1, C18:1, C24:1; and polyunsaturated
C18:2.6, C18:3.6, C18:3.3, C20:3, C20:4, C20:5.3, C20:5.3,
C22:6.
For biochemical analyses, blood samples were centrifuged
for 10 minutes at 3000 rpm, and plasma was separated. Two
milliliters of methanol/benzene (4:1) was added to 500 mL
plasma with 200 mg internal patron (C:17) diluted. Using
a magnetic stirrer, 200 mL acetyl chloride was added slowly.
Test tubes were sealed and heated at 100 C for 1 hour.
Following this, tubes were cooled with water, and 5 mL
K2CO3 (6%) was added before centrifugation for 5 minutes at
6000 rpm. From the benzenic extract obtained after centrifu-
gation, 2 mL were taken for injection into a gas chromatograph
(HP-5890 Series II. USA) coupled to a mass detector.
The chromatograph and detector conditions for the total
plasma fatty acids profile assays were as follows: carrier gas
He N-50, flow-rate 1 mL/min, split 6 mL/min, split ratio 27:1,
temperatures of 250 C at the detector and 300 C at the
injector pressure of 62.05 kPa at 185 C, and solvent delay
7.5 minutes. The column was a SUPELCO model Omegawax
(Sigma-Aldrich. USA) 320 of 30 m length  0.32 mm internal
diameter  0.25 mm film thickness. The oven temperature
program was: initial, 185 C for 15 minutes; first ramp, 3 C/
min to 190 C, 15 minutes; second ramp, 3 C/min to 245 C,
30 minutes. The detector emission current was 70 eV, and the
mass range was from 100 to 700 (m/z).
Fatty acid identification was performed by comparing their
retention times with spectra contained in spectra galleries. The
internal patron used for fatty acid quantification was hepta-
nodecanoic acid, due to it being well placed in the chro-
matogram and not interfering with other sample peaks. Plasma
fatty acid profile was expressed as a percentage. After
obtaining total plasma fatty acids, delta desaturase indexes
were calculated values as follows: delta 9.1: C16:1/C16:0,
delta 9.2: C18:1/C18:0 and delta 5: C20:4/C20:3.
Table 1
Peak performance and respiratory parameters in placebo and caffeine trials.
Time (min:s) Peak power (W) HR (bpm) VO2 (mL/kg/min) VCO2 (mL/min) VE (L/min) RR (rpm) RER
PLA 11:35  1:45 328  24 184  5 38.47  4.99 4050  598 123.1  22.3 47.7  8.4 1.46  0.14
CAF 12:08**  1:59 336*  24 190**  6 41.56*  6.50 4136  1183 136.2*  22.7 51.7  7.4 1.40*  0.13
Values represent mean  standard deviation; n ¼ 20. Significant difference between placebo versus caffeine trial at *p < 0.05 and **p < 0.01. CAF ¼ caffeine;
HR ¼ heart rate; RER ¼ respiratory exchange ratio; RR ¼ respiratory rate; VCO2 ¼ carbon dioxide consumption; VE ¼ minute ventilation; VO2 ¼ oxygen
consumption.
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that no caffeine ingestion took place before placebo or caffeine
trials and to assess concentrations after the caffeine trial. Plasma
caffeine was measured by high-performance liquid chromatog-
raphy (HPLC; Spectra SERIES P100/UV 100. UK).14
The experiments carried out in this study were governed by
the norms of investigation in the Declaration of Helsinki. The
Regional Government Ethics Committee provided permission
for the undertaking of this experiment.StatisticsSPSS for Windows version 16.0 was used for statistical
analysis. The KolmogoroveSmirnov test for normality
showed data to be not normally distributed, thus, the
nonparametric Wilcoxon test for paired (dependent) samples
was used. A value of p < 0.05 was used to determine statistical
significance.
Results
Peak values for performance and ventilatory parameters for
exercise trials under placebo and caffeine conditions are
shown in Table 1. Participants in the caffeine trial cycled
longer, achieved greater peak power output, heart rate and
relative oxygen consumption than in the placebo trial, whereas
the respiratory exchange ratio was lower.
Analysis of plasma caffeine concentration (via HPLC)
showed no presence of caffeine before or after placebo trials or
before caffeine ingestion, whereas mean plasma caffeine
concentration after the caffeine trial was 7.45  4.13 mg/mL.
Table 2 describes the proportion (%) of the different groups
of plasma fatty acids before and after the incremental maximal
trials under placebo and caffeine conditions. In the caffeine
trial, only plasma saturated fatty acids as a proportion of total
plasma fatty acids exhibited a significantly greater changeTable 2
Plasma fatty acid proportions in maximal exercise trials under placebo and caffein
Placebo trials
Initial (%) Final (%) Chang
Saturated 30.23  4.55 30.02  3.14 0.6
Monounsaturated 23.32  6.31 23.80  2.20 2.0
Polyunsaturated 46.43  5.77 46.19  3.44 0.5
u 6 42.46  5.45 41.32  3.38 2.6
u 3 3.97  1.36 4.87  1.84 þ22.6
Values represent mean  standard deviation; n ¼ 20. *Significant difference ( p < 0
observed in the caffeine trial.from the initial to final proportion ( p < 0.05) when compared
to changes in the placebo trial, with an increase in proportion
observed. For the other fatty acid groups shown in Table 2,
there were no differences in the proportional changes from
pre- to post-exercise between placebo and caffeine conditions.
Table 3 shows the proportions of individual plasma fatty
acids before and after exercise trials. Under caffeine condi-
tions, the decrease in the arachidic acid (C20:0) proportion
following exercise was the only saturated fatty acid to change
to a significant extent compared with that in the placebo trial
( p < 0.05). However, stearic acid (C18:0) did demonstrate
a trend towards a greater increase ( p ¼ 0.09) from its initial to
final proportion than that observed in the placebo trial. For
plasma monounsaturated fatty acids, trans-oleic acid (C18:1t)
was the only fatty acid whose change from its pre- to post-
exercise proportion was significantly different to that
observed in the placebo trial, with a decrease observed in the
caffeine trial ( p < 0.05). There were no plasma poly-
unsaturated fatty acid proportions that differed significantly
from their initial to final proportions as a result of maximal
exercise when comparing placebo to caffeine changes.
Table 4 shows lipid desaturation indexes before and after
maximal exercise in the placebo and caffeine trials. Lipid
desaturation indexes refer to the activity of desaturase
enzymes responsible for fatty acid desaturation. The calcu-
lated delta 9.2 index decreased to a greater extent in the
caffeine versus placebo trial ( p < 0.05), with no significant
changes observed in other desaturase indexes following
maximal exercise.
Discussion
In this placebo-controlled experiment involving incremental
exercise to volitional fatigue, the ingestion of 5 mg/kg BM
caffeine resulted in an improvement in exercise performance,
as demonstrated by a significantly greater time to exhaustion,e conditions.
Caffeine trials
e (%) Initial (%) Final (%) Change (%)
9 31.11  5.39 33.83  8.27 þ8.74*
6 25.64  8.77 23.69  4.69 7.61
2 43.23  12.23 42.46  7.13 1.78
8 39.29  11.61 38.99  6.31 0.76
7 3.94  1.19 3.47  1.23 11.93
.05) for % change (from initial to final) observed in the placebo trial versus that
Table 3
Plasma fatty acids proportions in maximal exercise trials under placebo and caffeine conditions.
Placebo trials Caffeine trials
Initial (%) Final (%) Change (%) Initial (%) Final (%) Change (%)
C12:0 0.73  0.77 0.58  0.65 20.55 1.03  0.07 1.29  1.08 þ25.24
C14:0 1.02  0.76 0.84  0.54 17.65 1.38  1.27 1.35  1.35 2.17
C16:0 20.11  3.44 19.69  2.73 2.09 19.99  3.97 19.32  6.42 3.35
C18:0 8.08  1.30 8.46  1.97 þ4.70 8.17  1.32 11.61  12.87 þ42.11
C20:0 0.27  0.28 0.40  0.31 þ48.15 0.52  0.33 0.24  0.15 53.85*
C16:1 1.61  0.85 1.70  1.19 þ5.59 1.59  0.54 1.54  0.41 3.14
C18:1c 19.23  5.95 17.78  5.47 7.54 20.01  3.43 19.68  4.21 1.65
C18:1t 1.52  0.66 2.84  4.47 þ86.84 3.22  6.19 1.73  0.43 46.27*
C24:1 0.95  0.33 1.47  1.53 þ54.74 0.82  0.37 0.73  0.35 10.98
C18:2.6 32.61  3.76 32.24  2.92 1.13 30.4  3.95 30.70  5.08 þ0.99
C18:3.6 0.29  0.21 0.36  0.20 þ24.14 0.30  0.14 0.26  0.14 13.33
C18:3.3 0.20  0.18 0.27  0.11 þ35.00 0.28  0.23 0.22  0.19 21.43
C20:3 1.94  0.94 1.68  0.53 13.40 1.72  0.62 1.59  0.34 7.56
C20:4 7.61  2.6 7.04  1.25 þ7.49 6.85  2.14 6.42  1.50 6.28
C20:5.3 0.86  0.6 0.98  0.4 þ13.95 1.00  0.70 0.86  0.28 14.00
C22:5.3 1.01  0.45 1.33  0.85 þ31.68 0.92  0.37 0.85  0.33 7.61
C22:6 1.89  1.09 2.29  1.08 þ21.16 1.72  0.59 1.52  0.63 11.63
Values represent mean  standard deviation; n ¼ 20. *Significant difference ( p < 0.05) for % change (from initial to final) observed in the placebo trial versus that
observed in the caffeine trial.
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improved exercise performance in the presence of elevated
plasma caffeine concentrations was associated with an increase
in relative fat oxidation as well as the novel finding of post-
exercise differences in individual free fatty acid proportions
when compared with the placebo condition.
In this study, we took the novel approach of assessing
plasma caffeine concentrations of each participant immedi-
ately after each exercise bout, rather than simply assuming that
the ingestion of exogenous caffeine had increased circulating
caffeine concentrations. The post-exercise plasma caffeine
concentrations of 7.45  4.13 mg/mL in the caffeine trials
substantiated the efficacy of the dosage, whereas the absence
of caffeine in plasma was verified in the placebo trials.
The increases observed in time to exhaustion, maximal
power output and maximal oxygen consumption following
caffeine ingestion are consistent with other studies.15e17 This
ergogenic effect of caffeine was associated with an increase
in relative fat oxidation, as reflected by lower respiratory
exchange ratio values, that may reflect a lesser reliance on
glycogen and a subsequent lower production of glycolytic
metabolites (e.g., lactate). These outcomes can ultimately lead
to a greater time to exhaustion. However, changes in subjective
effort perception associated with caffeine have beenTable 4
Lipid desaturation index in maximal exercise trials under placebo and caffeine co
Placebo trials
Initial Final Change (%
Delta 9.1 0.08  0.25 0.09  0.44 þ12.50
Delta 9.2 2.57  1.08 2.44  1.05 5.06
Delta 5 3.92  1.77 4.19  1.36 þ6.89
Values represent mean  standard deviation; n ¼ 20. *Significant difference ( p < 0
observed in the caffeine trial.identified,18 thus, adenosine receptor antagonism with
caffeine19 and the associated attenuation of pain and increased
arousal20 may also have contributed to the observed
improvement in exercise performance.
Saturated fatty acids as a proportion of the total plasma
fatty acid profile increased following exercise in the caffeine
trial, and this might reflect their greater mobilization for
oxidation during exercise.21 Alternatively, it might be
hypothesized that this is due to an increase in lipid perox-
idation and the consequent change from unsaturated to satu-
rated fatty acids,11 but our data showed no significant
decreases in plasma unsaturated fatty acids. Moreover, under
the same maximal exercise conditions as the present study,
increases in oxidative stress have not been observed with
caffeine ingestion.22 Therefore, it is likely that the increase in
the plasma saturated fatty acids proportion is due in part to
their greater mobilization for use as a source of energy during
maximal aerobic exercise. Further work investigating caffeine
and its influence on the plasma free fatty acid profile could be
performed at submaximal exercise intensities at which fat
oxidation nears maximal rates23 because, at these intensities,
changes in plasma fatty acids might be more marked.
This increase in the plasma saturated fatty acids proportion
following maximal exercise in the caffeine trial also appearednditions.
Caffeine trials
) Initial Final Change (%)
0.08  0.14 0.08  0.06 0
2.84  1.29 1.84  0.36 35.21*
3.98  1.45 4.04  1.41 þ1.51
.05) for % change (from initial to final) observed in the placebo trial versus that
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stearic acid (C18:0) and a decrease ( p < 0.05) in the mono-
unsaturated fatty acid, trans-oleic fatty acid (C18:1t). These
proportional changes in the two individual fatty acids result in
a decrease in the calculated lipid desaturation index, delta 9.2,
suggesting that caffeine inhibits delta desaturase enzymatic
activity. However, with delta desaturase activity here being
estimated through desaturation index calculations, direct
measures of the activity of this enzyme is required to verify
the proposed inhibition. Inhibition of delta-desaturase enzy-
matic activity could act to prevent decreases in stearic acid,
thereby helping to maintain availability of saturated fatty acids
as a substrate for exercise. It should also be noted that the
decrease in trans-oleic fatty acid (C18:1t) confers a potential
health benefit and provides a potential avenue through which
exercise with caffeine reduces the risk of cardiovascular heart
disease.24
It is important to bear in mind that any changes observed
post-exercise in the free fatty acids profile in the caffeine trial
cannot be considered the result of caffeine alone. In the
caffeine trial, exercise performance was enhanced and this
may have also contributed to the observed changes in circu-
lating substrate immediately post-exercise. For example, the
proposed increases in saturated fatty acid mobilization and
skeletal muscle use (as suggested by lower respiratory
exchange ratio values) of free fatty acids such as arachidic acid
and trans-oleic fatty acid may be the consequence of the
greater energy demands of a greater power output and exercise
time in the caffeine trial rather than solely the influence of
caffeine on substrate metabolism.
In conclusion, our data show that the ingestion of 5 mg/kg
BM caffeine at 60 minutes before incremental maximal
exercise provides an ergogenic benefit to untrained individ-
uals. Moreover, the interaction of this caffeine dosage and an
enhanced exercise performance induces significant changes in
the plasma total fatty acid profile, with specific changes in
individual fatty acid proportions within the total fatty acid
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